Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses
Nicolas Çuburu, … , Douglas R. Lowy, John T. Schiller
Nicolas Çuburu, … , Douglas R. Lowy, John T. Schiller
Published November 12, 2012
Citation Information: J Clin Invest. 2012;122(12):4606-4620. https://doi.org/10.1172/JCI63287.
View: Text | PDF
Research Article Immunology

Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses

  • Text
  • PDF
Abstract

The induction of persistent intraepithelial CD8+ T cell responses may be key to the development of vaccines against mucosally transmitted pathogens, particularly for sexually transmitted diseases. Here we investigated CD8+ T cell responses in the female mouse cervicovaginal mucosa after intravaginal immunization with human papillomavirus vectors (HPV pseudoviruses) that transiently expressed a model antigen, respiratory syncytial virus (RSV) M/M2, in cervicovaginal keratinocytes. An HPV intravaginal prime/boost with different HPV serotypes induced 10-fold more cervicovaginal antigen-specific CD8+ T cells than priming alone. Antigen-specific T cell numbers decreased only 2-fold after 6 months. Most genital antigen-specific CD8+ T cells were intra- or subepithelial, expressed αE-integrin CD103, produced IFN-γ and TNF-α, and displayed in vivo cytotoxicity. Using a sphingosine-1-phosphate analog (FTY720), we found that the primed CD8+ T cells proliferated in the cervicovaginal mucosa upon HPV intravaginal boost. Intravaginal HPV prime/boost reduced cervicovaginal viral titers 1,000-fold after intravaginal challenge with vaccinia virus expressing the CD8 epitope M2. In contrast, intramuscular prime/boost with an adenovirus type 5 vector induced a higher level of systemic CD8+ T cells but failed to induce intraepithelial CD103+CD8+ T cells or protect against recombinant vaccinia vaginal challenge. Thus, HPV vectors are attractive gene-delivery platforms for inducing durable intraepithelial cervicovaginal CD8+ T cell responses by promoting local proliferation and retention of primed antigen-specific CD8+ T cells.

Authors

Nicolas Çuburu, Barney S. Graham, Christopher B. Buck, Rhonda C. Kines, Yuk-Ying S. Pang, Patricia M. Day, Douglas R. Lowy, John T. Schiller

×

Figure 10

HPV Ivag, but not Ad5 i.m., prime/boost immunization induces intraepithelial CD8+ T cells in the cervicovaginal epithelium.

Options: View larger image (or click on image) Download as PowerPoint
HPV Ivag, but not Ad5 i.m., prime/boost immunization induces intraepithe...
Depo-Provera–treated mice were immunized with 5 × 107 IU HPV16MM2 Ivag or with 5 × 107 PFU Ad5-MM2 i.m., and 1 month later mice were immunized with 5 × 107 IU HPV45MM2 or Ad5-MM2 i.m., respectively. (A) Two weeks after the last immunization, cervicovaginal tissue sections were co-stained for CD8 (green), CD3 (red), laminin 332 (magenta), and nuclei (blue). Scale bars: 50 μm. Images are representative of 5 animals tested for each condition examined. (B) In separate experiments, CD103 expression by KdM282-tetramer+CD8+ T lymphocytes was analyzed by flow cytometry in cervicovaginal, ILN, and blood cell suspensions from HPV Ivag and Ad5 i.m. immunized animals. Control isotype (red lines) and CD103 antibody (blue lines) staining is shown in B, and the percentage of CD103+ cells is indicated in the histogram plots. Data are representative of 3 experiments.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts